Believe I alluded to TF t/o target(s) with their cash war chest of xxxxmillions of dollars and purchase of another bio Co. for $200+ cash. They got the dosh ready to spend and unfortunately in some respects expect them to snap us up on the cheap post positive legal outcome......
all the T/O talk is exciting on the one hand but rather limiting on the other. Attaining an sp which reflects our value can be a moving target with huge fluctuations due to market conditions. So full value comes and goes.
The prospect of T/O was first seen by me when the desire to engage T/O was expressed by Dr Little say 15 mths ago ??
This might suggest that the vision of the BOD is relatively short sighted.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Initially we heard about the prospects of applying our tech to oncology but month after month no suggestion we are even doing research to open this door which would vastly broaden our spectrum of offer not to mention getting us into a highly favored and relevant field of endeavour.
But this would by definition need a long term vision and commitment by the Board and lets face it we havnt been given that other than the conditions on options dished out to the founders.
I would very welcome expressions of intent to go after a place in the oncology theater of offers and our presence would be witnessed by regular reporting of progress.
The fact that we hear nothing is indicative that there is at the moment no intent and thats a shame.
I have been fortunate to be involved in a Co which started out with one product which was cutting edge tech but over the last decade has developed the foot print to cover many products applicable to many high tech applications. This is all acheiveable only because of the ambition and mind set of the MD/Chairman of this Co.
The question suggests that the reason for producing, yet another, Hardman report was for other audiences and purposes rather than providing private PIs a wrap-up after a transformational period of time. Certainly it is very strange timing given that it is nearly Year End and one would be expecting a Trading Statement. It could be probably that they were trying to put the expected figures in context or otherwise there may now not be plans to supply a trading statement after Year End. Who knows maybe with the previous RNS on Trade Shows they wanted to draw a line before further news.
What I cannot understand is how conservative the growth is. To put it in context the global non-invasive prenatal testing (NIPT) market was valued at $563.4 million in 2014, and it was then expected to grow with a CAGR of 17.6% during the period 2015 - 2020. Essentially the NIPT market is to be worth USD 2.3 Billion by 2020. However this figure is dwarfed by the sequencer sales. Although the rate of growth in 2018/9 sales are impressive tthe sales are dwarfed by Natera and Sequenom. IONA as one of the few independent NIPT providers on the Thermo Fisher sequencer would need to be made up to step up a gear to contribute meaningfully in the wider strategic game. As such although constantly disappointed I still cannot believe that Premaitha will be allowed the grace to grow organically at their own pace till late 2018.
With the acquisition completed 3 YourGene BoD members have now joined either the Premaitha Management Team or BoD. What is surprising is that the Illumina HiSeq 2500 is still being marketed by the new Chief Scientific Officer on their YourGene website. So maybe the relations are more warmer than we think.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.